The work on this project was directed towards the development of a phase I, randomized, placebo-controlled, dose-escalation study of a multicomponent HIV-1 adenoviral vector vaccine. The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to HIV-1. The proposed protocol design is to enroll subjects who will be randomly assigned to vaccine or PBS control injections. If there are no significant toxicities, dose escalation will be initiated.
Cheng, Cheng; Gall, Jason G D; Kong, Wing-pui et al. (2007) Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3:e25 |
Sheets, R L (2006) Adventitious agent test methods. Dev Biol (Basel) 123:135-45; discussion 183-97 |
Sheets, Rebecca (2006) Assaying potency of novel vaccines. October 11-12, 2005, Bethesda, MD, USA. Expert Rev Vaccines 5:315-8 |
Butman, B T; Lizonova, A; Brough, D E et al. (2006) Comprehensive characterization of the 293-ORF6 cell line. Dev Biol (Basel) 123:225-33; discussion 265-6 |